Effect of the Thiotepa Dose in the TBF Conditioning Regimen in Patients Undergoing Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia in Complete Remission: A Report From the EBMT Acute Leukemia Working Party.

[1]  D. Blaise,et al.  Thiotepa, Fludarabine, and Busulfan Conditioning Regimen before T Cell-Replete Haploidentical Transplantation with Post-Transplant Cyclophosphamide for Acute Myeloid Leukemia: A Bicentric Experience of 100 Patients. , 2019, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[2]  J. Esteve,et al.  Sorafenib improves survival of FLT3-mutated acute myeloid leukemia in relapse after allogeneic stem cell transplantation: a report of the EBMT Acute Leukemia Working Party , 2019, Haematologica.

[3]  M. Mohty,et al.  Efficacy and Feasibility of Sorafenib as a Maintenance Agent After Allogeneic Hematopoietic Stem Cell Transplantation for Fms-like Tyrosine Kinase 3 Mutated Acute Myeloid Leukemia: An Update. , 2019, Clinical lymphoma, myeloma & leukemia.

[4]  D. Blaise,et al.  Prophylactic donor lymphocyte infusions after haploidentical haematopoietic stem cell transplantation for high risk haematological malignancies: a retrospective bicentric analysis of serial infusions of increasing doses of CD3+ cells , 2018, British journal of haematology.

[5]  R. Mahfouz,et al.  Feasibility of Venetoclax-based combinations for adult patients with acute myeloid leukemia relapsing after allogenic stem cell transplantation , 2018, Bone Marrow Transplantation.

[6]  E. Purev,et al.  Thiotepa-Based Intensified Reduced-Intensity Conditioning Adult Double-Unit Cord Blood Hematopoietic Stem Cell Transplantation Results in Decreased Relapse Rate and Improved Survival Compared with Transplantation Following Standard Reduced-Intensity Conditioning: A Retrospective Cohort Comparison. , 2018, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[7]  R. Mahfouz,et al.  Thiotepa 10 mg/kg Treatment Regimen Is Superior to Thiotepa 5 mg/kg in TBF Conditioning in Patients Undergoing Allogeneic Stem‐Cell Transplantation , 2018, Clinical lymphoma, myeloma & leukemia.

[8]  Tae Kon Kim,et al.  Hypomethylating agents in relapsed and refractory AML: outcomes and their predictors in a large international patient cohort. , 2018, Blood advances.

[9]  U. Germing,et al.  Hypomethylating agents for treatment and prevention of relapse after allogeneic blood stem cell transplantation , 2018, International Journal of Hematology.

[10]  R. Mahfouz,et al.  Low-dose 5-azacytidine as preventive therapy for relapse of AML and MDS following allogeneic HCT , 2017, Bone Marrow Transplantation.

[11]  D. Blaise,et al.  Prophylactic donor lymphocyte infusion after allogeneic stem cell transplantation for high-risk AML , 2017, Bone Marrow Transplantation.

[12]  B. George,et al.  Allogeneic Stem Cell Transplant for Acute Myeloid Leukemia: Evolution of an Effective Strategy in India , 2017, Journal of global oncology.

[13]  Stephanie J. Lee.  Classification systems for chronic graft-versus-host disease. , 2017, Blood.

[14]  P. Thall,et al.  Fludarabine with pharmacokinetically-guided IV busulfan is superior to fixed-dose delivery in pretransplant conditioning of AML/MDS patients , 2016, Bone Marrow Transplantation.

[15]  C. Tresoldi,et al.  High rate of hematological responses to sorafenib in FLT3‐ITD acute myeloid leukemia relapsed after allogeneic hematopoietic stem cell transplantation , 2016, European journal of haematology.

[16]  M. Labopin,et al.  Thiotepa‐based versus total body irradiation‐based myeloablative conditioning prior to allogeneic stem cell transplantation for acute myeloid leukaemia in first complete remission: a retrospective analysis from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantati , 2016, European journal of haematology.

[17]  M. Bar,et al.  Biology of Blood and Marrow Transplantation , 2015 .

[18]  R. Mahfouz,et al.  Azacitidine Maintenance after Allogeneic Stem Cell Transplantation Is Feasible in Patients with Acute Myeloid Leukemia and Myelodysplasia , 2014 .

[19]  F. W. Jamaluddin,et al.  Comparison of reduced-intensity and myeloablative conditioning regimens for allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia and acute lymphoblastic leukemia: a meta-analysis. , 2014, Stem cells and development.

[20]  P. Piccaluga,et al.  Conditioning regimens in acute myeloid leukemia , 2014, Expert review of hematology.

[21]  C. Solano,et al.  Single-unit umbilical cord blood transplantation from unrelated donors in patients with hematological malignancy using busulfan, thiotepa, fludarabine and ATG as myeloablative conditioning regimen , 2012, Bone Marrow Transplantation.

[22]  S. Fruchtman,et al.  Stem cell transplantation , 1999, HemaSphere.

[23]  M. Sanz,et al.  Cord blood transplantation from unrelated donors in adults with high-risk acute myeloid leukemia. , 2010, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[24]  F. Appelbaum.  Optimising the conditioning regimen for acute myeloid leukaemia. , 2009, Best practice & research. Clinical haematology.

[25]  M. Eilers,et al.  Compassionate use of sorafenib in FLT3-ITD-positive acute myeloid leukemia: sustained regression before and after allogeneic stem cell transplantation. , 2009, Blood.

[26]  D. Jacobsohn,et al.  Acute graft-versus-host disease. , 1990, Cancer treatment and research.

[27]  A. Pileri,et al.  Reduced-intensity conditioning followed by allografting of hematopoietic cells can produce clinical and molecular remissions in patients with poor-risk hematologic malignancies. , 2002, Blood.

[28]  F. Benvenuto,et al.  Thiotepa Cyclophosphamide Followed by Granulocyte Colony-Stimulating Factor Mobilized Allogeneic Peripheral Blood Cells in Adults With Advanced Leukemia , 1996 .

[29]  F. Benvenuto,et al.  Thiotepa cyclophosphamide followed by granulocyte colony-stimulating factor mobilized allogeneic peripheral blood cells in adults with advanced leukemia. , 1996, Blood.

[30]  P. Hougaard,et al.  Frailty models for survival data , 1995, Lifetime data analysis.